The Japan Age-Related Macular Degeneration (AMD) Market is expected to reach US$ 897.79 million by 2033 from US$ 526.46 million in 2024, with a CAGR of 6.11% from 2025 to 2033. The market is being driven by an increase in the prevalence of eye problems. Medical therapy for age-related macular degeneration will rise as a result of a developing market trend, such as the creation of gene therapy for the condition.
Innovative medicines to manage and treat AMD are being actively developed by pharmaceutical and biotech businesses in Japan. Treatments for both the wet and dry forms of AMD are available on the market, ranging from anti-VEGF (vascular endothelial growth factor) injections to new gene and cell therapies. Advanced therapeutic alternatives are being introduced more quickly thanks to growing research agreements between international organizations and Japanese companies. The dynamic environment of the AMD business in Japan is further influenced by regulatory frameworks that encourage quicker approval of new medications and government funding for healthcare innovation.
Notwithstanding the encouraging development possibilities, obstacles including exorbitant treatment costs and accessibility problems still exist, especially in rural areas with a shortage of specialized ophthalmology care. Furthermore, increasing public knowledge of AMD and the value of early diagnosis continues to be a top priority for healthcare stakeholders. It is anticipated that ongoing initiatives to boost patient education, improve insurance coverage, and upgrade healthcare infrastructure will further propel market expansion. All things considered, the AMD market in Japan is expected to expand due to changes in the population, advances in technology, and a growing focus on preventive eye care.
Tokyo has responded by implementing state-of-the-art therapies to treat both wet and dry forms of AMD, such as gene therapies and anti-VEGF therapies. Tokyo is at the forefront of AMD management in Japan thanks to its dedication to healthcare innovation and research, which also encourages the development of cutting-edge therapeutic approaches.
Japan Age-Related Macular Degeneration Market Overview
Japan's rapidly aging population is driving tremendous growth in the Age-Related Macular Degeneration (AMD) business. With Japan having one of the highest percentages of senior people worldwide, AMD is a major cause of visual loss in older persons. As a result, there is a growing need for efficient diagnostic and treatment alternatives. The prevention of severe visual impairment depends on the earlier and more precise detection of AMD, which is made possible by advancements in medical technology, such as imaging and diagnostic equipment. This has prompted medical professionals to invest in specialist ophthalmic care facilities and implement thorough screening procedures.Innovative medicines to manage and treat AMD are being actively developed by pharmaceutical and biotech businesses in Japan. Treatments for both the wet and dry forms of AMD are available on the market, ranging from anti-VEGF (vascular endothelial growth factor) injections to new gene and cell therapies. Advanced therapeutic alternatives are being introduced more quickly thanks to growing research agreements between international organizations and Japanese companies. The dynamic environment of the AMD business in Japan is further influenced by regulatory frameworks that encourage quicker approval of new medications and government funding for healthcare innovation.
Notwithstanding the encouraging development possibilities, obstacles including exorbitant treatment costs and accessibility problems still exist, especially in rural areas with a shortage of specialized ophthalmology care. Furthermore, increasing public knowledge of AMD and the value of early diagnosis continues to be a top priority for healthcare stakeholders. It is anticipated that ongoing initiatives to boost patient education, improve insurance coverage, and upgrade healthcare infrastructure will further propel market expansion. All things considered, the AMD market in Japan is expected to expand due to changes in the population, advances in technology, and a growing focus on preventive eye care.
Key Factors Driving the Japan Age-Related Macular Degeneration (AMD) Market Growth
Growing Prevalence and Aging Population
The Age-Related Macular Degeneration (AMD) market in Japan is mostly driven by the country's aging population. Japan has one of the longest life expectancies in the world and an increasing senior population, which makes them the most vulnerable to AMD. The incidence of AMD naturally increases with population age, increasing the need for diagnosis, treatment, and long-term management strategies. Healthcare professionals are compelled by this demographic trend to increase their ophthalmic services, screening programs, and patient education campaigns that emphasize early identification and prevention. Furthermore, senior eye health is becoming a higher priority in government healthcare plans, which makes AMD-related care more accessible. Thus, the growing patient base encourages continued expansion and investment in the AMD business in Japan.Developments in Diagnostic Technologies
Japan's AMD market expansion is mostly driven by technological advancements in diagnostic equipment. Ophthalmologists can identify AMD earlier and more accurately thanks to sophisticated imaging techniques like fundus photography, fluorescein angiography, and optical coherence tomography (OCT). Timely treatment, better patient outcomes, and vision preservation all depend on early diagnosis. The availability of these advanced diagnostic tools in Japanese clinics and hospitals has increased, increasing screening rates and disease surveillance. Additionally, studies on novel biomarkers and non-invasive diagnostic techniques should improve detection even more. AI and telemedicine integration in eye care is also starting to facilitate remote diagnosis and patient monitoring, increasing accessibility and effectiveness in the treatment of AMD.Launch of Innovative Medicines
The creation and launch of novel treatments are important factors propelling the AMD industry in Japan. Although gene therapies, regenerative medicine, and long-acting drug delivery systems are recent developments, anti-VEGF agents are still the gold standard for treating wet AMD. In order to address unmet clinical needs in both wet and dry AMD forms, these novel treatments seek to increase efficacy, decrease injection frequency, and minimize side effects. Global biotech companies and Japanese pharmaceutical companies work together to expedite the regulatory approval and drug development processes. New therapeutics can enter the market more easily thanks to government support for healthcare innovation and expedited approval processes. When combined, these developments increase patient adherence, broaden therapy alternatives, and propel market expansion.Challenges in the Japan Age-Related Macular Degeneration (AMD) Market
Exorbitant Medical Expenses and Problems with Reimbursement
The high expense of cutting-edge treatments is one of the main issues facing the AMD market in Japan. Gene treatments, regenerative medicine, and anti-VEGF injections are examples of novel therapeutics that frequently have high cost. Even though Japan's universal healthcare system reimburses patients, complicated regulations and co-payment requirements may restrict access, particularly for older people with fixed incomes. These financial obstacles could have a detrimental effect on patient outcomes by delaying the start of treatment or causing irregular therapy adherence. Furthermore, healthcare practitioners have to deal with lengthy reimbursement approval procedures, which may impede the uptake of novel treatments. Expanding access and guaranteeing fair treatment availability for all members of the community still depend on resolving issues with cost and reimbursement.Limited Accessibility and Awareness in Rural Areas
Although Japan's cities have sophisticated ophthalmic care systems, rural and isolated areas have little access to specialized services for AMD diagnosis and treatment. Inadequate disease management and delayed diagnosis are caused in part by the lack of qualified ophthalmologists and sophisticated diagnostic tools in these regions. Furthermore, underdiagnosis and late-stage presentations result from a lack of knowledge about AMD symptoms and the significance of early treatments in less urbanized regions. While underway, efforts to enhance public education, telemedicine acceptance, and healthcare infrastructure need more funding and coordination. To guarantee comprehensive AMD care and lessen inequities in treatment outcomes across the country, it is imperative to increase accessibility and awareness in rural Japan.Japan Age-Related Macular Degeneration (AMD) Market Regional Analysis
Tokyo Age-Related Macular Degeneration (AMD) Market
Tokyo, the capital of Japan and a major international city, is crucial to the Age-Related Macular Degeneration (AMD) market in that nation. Residents are guaranteed access to cutting-edge AMD diagnostic and treatment services thanks to the city's sophisticated healthcare infrastructure and high concentration of specialized ophthalmic centers. Given Tokyo's aging population, which reflects the national trend of an increasing number of older people at risk for AMD, this is especially important. Longer life expectancy and an urban lifestyle are two variables that contribute to the occurrence of AMD in Tokyo, making comprehensive eye care services necessary.Tokyo has responded by implementing state-of-the-art therapies to treat both wet and dry forms of AMD, such as gene therapies and anti-VEGF therapies. Tokyo is at the forefront of AMD management in Japan thanks to its dedication to healthcare innovation and research, which also encourages the development of cutting-edge therapeutic approaches.
Kansai Age-Related Macular Degeneration (AMD) Market
Leading ophthalmic institutes and a sophisticated healthcare system support the AMD market in Japan's Kansai region, which includes cities like Osaka, Kyoto, and Kobe. The area is home to renowned research facilities and pharmaceutical businesses, such as Osaka-based Santen Pharmaceutical, which specializes in ophthalmic goods and has a significant domestic market presence. Additionally, Kansai is at the forefront of developing regenerative medicine. Kobe hospitals are developing retinal treatments for AMD based on iPS-cells, and they have applied for insurance coverage under advanced medical care frameworks. These capabilities position Kansai as a center for both modern AMD care and innovation in Japan by supporting a wide range of diagnosis and treatment options, such as anti-VEGF therapies and clinical trials of innovative regenerative approaches.Aichi Age-Related Macular Degeneration (AMD) Market
Thanks to a state-of-the-art healthcare system and rising local awareness of eye health, Aichi Prefecture, which is centered on Nagoya, is becoming a major center for AMD care in Japan. The area benefits from well-established diagnostic facilities and ophthalmic clinics with cutting-edge imaging technologies including fundus photography and OCT, which are crucial for the early detection of AMD. Anti-VEGF treatments are becoming more widely available to patients as Japanese researchers and medical professionals give priority to AMD, including neovascular (wet) and dry forms. The healthcare system in Nagoya fosters innovation and service delivery, even though the majority of AMD research is centered in other locations. Aichi is becoming a more significant regional participant in Japan's AMD ecosystem as a result of ongoing initiatives to improve early detection, treatment accessibility, and public education.Market Segmentation
Disease Type
- Dry Age-Related Macular Degeneration Market
- Wet Age-Related Macular Degeneration Market
Product
- Eylea
- Lucentis
- Beovu
- Others
Distribution Channel
- Hospital Pharmacy
- Specialty Pharma
- Online Pharmacy
Cities
- Tokyo
- Kansai
- Aichi
- Kanagawa
- Saitama
- Hyogo
- Chiba
- Hokkaido
- Fukuoka
- Shizuoka
All the Key Players Have Been Covered
- Overview
- Key Persons
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Company Analysis
- F. Hoffmann - La Roche Ltd.
- Bayer AG
- Abbvie
- GSK Plc
- Novartis AG
- Regeneron Pharmaceuticals
- Bausch Health Companies Inc.
- Alimera Sciences Inc.
Table of Contents
1. Introduction3. Executive Summary11. Value Chain Analysis14. Regulations and Reimbursement
2. Research & Methodology
4. Market Dynamics
5. Japan Age-Related Macular Degeneration (AMD) Market
6. Market Share Analysis
7. Disease Type
8. Product
9. Distribution Channel
10. Top 10 City
12. Porter's Five Forces Analysis
13. SWOT Analysis
15. Pricing Benchmark Analysis
16. Key Player Analysis
Companies Mentioned
The major companies profiled in this Japan Age-Related Macular Degeneration market report include:- F. Hoffmann - La Roche Ltd.
- Bayer AG
- Abbvie
- GSK Plc
- Novartis AG
- Regeneron Pharmaceuticals
- Bausch Health Companies Inc.
- Alimera Sciences Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | July 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 526.46 Million |
| Forecasted Market Value ( USD | $ 897.79 Million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Japan |
| No. of Companies Mentioned | 9 |
